Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
A midlife PSA value above the 90th percentile was associated with greater risk of total and aggressive prostate cancer in black men.
A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
Findings for men with intermediate- and high-risk prostate cancer.